A web-based analytical platform to tease apart genomic data just raised some cash: Utah-based genome analysis company Tute Genomics held a $2.3 million Series A1 round.
Investors include Eurovestech, Peak Ventures and several angel investors, Tute Genomics said in a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s cloud-base analytics platform is meant to be used by labs, clinicians and researchers to “unlock the genome, personalize treatment and power discovery.” Tute Genomics says it’s processed nearly 10,000 genome samples, and it has a number of as-yet-unnamed commercial agreements in place.
“One of the main barriers to making personalized, genome-guided medicine a reality is data analysis, and Tute’s platform drastically decreases the complexity and cost of analyzing genomic data sets,” Tute Genomics CEO Reid Robison said in a statement. He added that the investment will help the company’s goal of “bringing genomic insights into routine medical practice.”
The company’s biomarker and gene discovery tool was designed by a team of scientists led by Kai Wang – the guy that developed Annovar, a commonly used tool meant for functional annotation of gene variants.
Gene analysis platforms are aplenty, but here’s how Tute says it stands out from the pack:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Tute’s novel approach transforms and accelerates data analysis from a simple output list of variants to a full interpretation of sequencing data, and does so in a fraction of the time of other tools. Not only does Tute perform gene, region and filter based annotation pulling from numerous definition systems and annotations to identify individual variants, it is also capable of conducting multiple sample studies to prioritize the identification of disease genes in a family or population, offering the knowledge of corresponding clinical implications in a summary report.
